Clinical Trial Update: Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of MEDI2070 in active moderate-to-severe Crohn's disease (results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• MEDI2070

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-03-06